Multivalent Pneumococcal Vaccine Complexes for Broad T-Cell Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Streptococcus pneumoniae, such as PCV13 and PPSV23, fail to provide long-lasting T-cell dependent immunity against a broad range of serotypes, leaving a significant medical need for improved vaccines that can protect against invasive pneumococcal disease and pneumonia.
Innovation Solution
A vaccine comprising immunogenic complexes formed by non-covalently associating biotinylated polysaccharide antigens of Streptococcus pneumoniae with fusion proteins, including biotin-binding moieties and specific polypeptide antigens like SP1500 and SP0785, to induce a robust T- and B-cell response across multiple serotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If polysaccharide capsules of S. pneumoniae are used to divide into different serotypes, then the ability to target specific serotypes is improved, but the complexity of developing vaccines against all serotypes increases
Solution Approach 1:
The patent combines multiple polysaccharide antigens from different serotypes into a single multivalent vaccine formulation. This merging approach allows the vaccine to target multiple serotypes simultaneously, resolving the contradiction by achieving broad serotype coverage without requiring separate vaccines for each serotype.
Solution Approach 2:
The vaccine formulation is designed to serve multiple functions by incorporating polysaccharide antigens from numerous serotypes. This multi-functional approach enables a single vaccine to provide protection against diverse serotypes, addressing the need for broad adaptability while maintaining a unified vaccine product.
2Adaptability or versatility
If PPSV23 includes polysaccharide components of more serotypes than PCV13, then the serotype coverage is improved, but the immune response becomes neither long-lasting nor anamnestic
Solution Approach 1:
The patent uses T-cell epitopes as intermediaries to bridge the gap between polysaccharide antigens and the immune system. These epitopes act as mediators that activate T-cells, which in turn enhance B-cell responses to the polysaccharide antigens, resulting in long-lasting and anamnestic immune responses while maintaining broad serotype coverage.
Solution Approach 2:
The vaccine employs a composite structure combining polysaccharide antigens with T-cell epitopes. This composite material design allows the vaccine to simultaneously achieve broad serotype coverage through the polysaccharide components and long-lasting immune responses through the T-cell epitope-mediated immune activation.
3Reliability
If current vaccines PCV13 and PPSV23 are used, then some protection is provided, but T-cell dependent immunity against a broad range of serotypes is not achieved
Solution Approach 1:
The patent merges polysaccharide antigens with T-cell epitopes to create a vaccine that provides both reliable protection and broad serotype coverage. This combination approach resolves the contradiction by achieving both high reliability through T-cell dependent immunity and broad adaptability through inclusion of multiple serotype antigens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine induces a broad immune response against a wide range of Streptococcus pneumoniae serotypes, providing effective protection against invasive pneumococcal disease and pneumonia.
Implementation Method 1
the biotinylated polysaccharide antigen is non-covalently associated with the biotin-binding moiety of the fusion protein to form an immunogenic complex
Data Source
AI summary
Technologies for the prevention and/or treatment of pneumococcal infections.